2648.0000 39.50 (1.51%)
NSE Nov 20, 2026 15:31 PM
Volume: 540.2K
 

2648.00
1.51%
ICICI Securities Limited
Glenmark Pharmaceuticals (Glenmark)’s Q1FY27 revenue was better our estimates, although EBITDA and profits lagged expectations. Strong growth across India (+15.5% YoY), US (+8.5% YoY) and emerging markets (+27.7% YoY) drove the revenue outperformance.
Number of FII/FPI investors increased from 473 to 502 in Sep 2026 qtr.
More from Glenmark Pharmaceuticals Ltd.
Recommended